Medpace (MEDP)
(Delayed Data from NSDQ)
$333.45 USD
-0.35 (-0.10%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $334.83 +1.38 (0.41%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$333.45 USD
-0.35 (-0.10%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $334.83 +1.38 (0.41%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth A Momentum A VGM
Zacks News
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
by Zacks Equity Research
Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.
Thermo Fisher (TMO) New Facility to Advance Lab Products Supply
by Zacks Equity Research
Thermo Fisher's (TMO) new manufacturing facility will help the United States meet demand surges for vital laboratory products.
Bruker (BRKR) Advances in Proteomics Workflow With New Pacts
by Zacks Equity Research
Talking about these three developments, Bruker (BRKR) notes that because of complex sample preparation protocols, the widespread adoption of proteomics has been limited.
Illumina (ILMN) iHope Genetic Health Program Expands WGS Access
by Zacks Equity Research
Illumina's (ILMN) launch of iHope Genetic Health program will expand access to WGS to low- and middle-income communities worldwide.
NuVasive (NUVA) Up on Rumors of Takeover by Globus Medical
by Zacks Equity Research
NuVasive's (NUVA) declining spine implant business might get a boost if its consolidation with Globus Medical takes place.
Here's Why You Should Retain STERIS (STE) Stock For Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to its strong fiscal second-quarter results and bullish 2022 outlook.
Medtronic's (MDT) PillCam SB3 System Gets 510 (k) Clearance
by Zacks Equity Research
Medtronic's (MDT) PillCam SB3 System provides a convenient option for a contactless procedure and helps ensure that patients can access care promptly.
Abbott (ABT) Aveir System Meets Primary Pivotal Trial Endpoints
by Zacks Equity Research
Abbott's (ABT) Aveir pacing system has the potential to advance treatment for patients who need a pacemaker but where physicians are concerned about more invasive surgery.
Here's Why You Should Add LabCorp (LH) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by consistent recovery across its businesses and raised 2021 guidance.
Alcon (ALC) Q3 Earnings Beat Estimates, Margin Improves
by Zacks Equity Research
Alcon (ALC) records year-over-year growth across all sales categories in Surgical and Vision Care in Q3.
Surmodics (SRDX) Stock Loses 2.2% Despite Q4 Earnings Beat
by Zacks Equity Research
Surmodics' (SRDX) fiscal fourth-quarter results reflect benefits from segmental strength.
Here's Why You Should Retain Edwards Lifesciences (EW) Stock
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on strong third-quarter results and bullish 2021 guidance.
National Vision (EYE) Q3 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
Strength in America's Best and Eyeglass World brands drove National Vision's (EYE) revenues in the third quarter of 2021.
Haemonetics (HAE) Q2 Earnings Lag Estimates, Gross Margin Grows
by Zacks Equity Research
Haemonetics (HAE) revenues increased year over year in the fiscal second quarter, supported by recovery across major businesses, especially Hospital and the initial Plasma Persona rollouts.
Cardiovascular Systems (CSII) Q1 Loss Wider Than Expected
by Zacks Equity Research
Cardiovascular Systems' (CSII) coronary franchise registers strong performance globally on continued strength in Japan and Europe.
SmileDirectClub (SDC) Q3 Earnings Lag Estimates, Margin Grows
by Zacks Equity Research
SmileDirectClub (SDC) registered a year-over-year decline in revenues in the third quarter due to lower unique aligner shipment.
Hill-Rom (HRC) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Strong underlying performance and continued recovery across all three business segments drove Hill-Rom's (HRC) fourth-quarter fiscal 2021 revenues.
Insulet (PODD) Q3 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
Insulet (PODD) reports better-than-expected revenues for third-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.
STERIS (STE) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Solid growth across all three reporting segments drove STERIS' (STE) second-quarter fiscal 2022 revenues.
Tandem Diabetes (TNDM) Q3 Earnings Top Estimates, Sales View Up
by Zacks Equity Research
Tandem Diabetes (TNDM) reports better-than-expected revenues for third-quarter 2021 as strong domestic and international pump shipments drive the top line.
Omnicell (OMCL) Q3 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Growth across both the operating segments of Omnicell (OMCL) contributes to Q3 top-line growth.
CVS Health (CVS) Q3 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Strength in all three operating segments drove CVS Health's (CVS) revenues in the third quarter of 2021.
Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business registered an improvement in revenues during the third quarter on strong contributions from Cologuard volume growth.
Myriad Genetics (MYGN) Q3 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment drove Q3 sales despite a challenging business environment.
Henry Schein (HSIC) Q3 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the third quarter.